ADALTA LIMITED (1AD)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
1AD - ADALTA LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.022
03 Oct |
OPEN $0.02 |
HIGH $0.02 |
0 LOW $0.02 |
0.001| OTHER COMPANIES IN THE SAME SECTOR | |||
| ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -1.5 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | - |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 0.5 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -5.1 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | - |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -133.12 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -108.99 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -52.78 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -133.12 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -108.99 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -5.1 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | - |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 5 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 4.61 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | - |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 0 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 8 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 4 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
1AD STOCK CHART
FNArena News on 1AD
| 1 |
Weekly Ratings, Targets, Forecast Changes – 19-08-19Aug 19 2019 - Weekly Reports |
| 2 |
AdAlta Advances With Pulmonary Fibrosis TreatmentSep 14 2016 - Small Caps |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
| 2 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |
| 3 |
Breaking Boundaries: Medical PsychedelicsAug 21 2023 - Small Caps |
| 4 |
Momentum Keeps Building For Avita MedicalAug 15 2023 - Small Caps |
| 5 |
Dr Boreham’s Crucible: IDT AustraliaAug 14 2023 - Small Caps |
| 6 |
Treasure Chest: Less Smooth Road Ahead For CSLAug 01 2023 - Treasure Chest |
| 7 |
Dr Boreham’s Crucible: Telix PharmaceuticalsJul 31 2023 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Arovella TherapeuticsJul 17 2023 - Small Caps |
| 9 |
Dr Boreham’s Crucible: PolyNovoJul 06 2023 - Small Caps |
| 10 |
CSL Disappoints But Brokers Retain The FaithJun 15 2023 - Australia |
